Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie

This study is tracking how well a biosimilar version of bevacizumab (brand name Elovie) works for people with advanced colorectal cancer that has spread. Biosimilars are medications that work essentially the same as an already-approved drug. This is a real-world observational study — researchers are collecting data from patients already receiving this treatment. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with stage IV (metastatic) colorectal cancer that cannot be surgically removed - You are currently receiving Elovie as your first-line treatment, or you recently switched to Elovie from another bevacizumab and have completed at least 1 treatment cycle - You are able to give informed consent **You may NOT be eligible if...** - You have been treated with Elovie for more than 12 cycles already - You previously received another bevacizumab for more than 2 cycles before switching to Elovie - You have another active cancer in addition to colorectal cancer - You used bevacizumab in a way not described in the official Elovie prescribing information Talk to your doctor to see if this trial is right for you.